Ablin R J
Eur Surg Res. 1976;8(6):481-4. doi: 10.1159/000127894.
While receiving only cursory attention compared to that of other malignant neoplasms, studies of patients with prostatic cancer have suggested that host responses, mediated in part by immunobiologic factors, may play a significant role in the pathogenesis and thus, the therapeutic management of this disease. For nearly a decade cryosurgery has gradually attained some degree of acceptance as one of the efficacious treatment modalities available in the therapeutic armamentarium for prostatic cancer. In addition to the localized destruction of the primary tumour, reports of secondary tumour cell destruction, i.e. of distant metastases, have supported the suggestion that cryosurgery, as documented in various animal species, may also be immunopotentiating in man. Although our understanding of immunopotentiation of the host's response to tumour via cryosurgery is far from complete, information derived from experimental studies demonstrating that the developement of an immunologic response following cryosurgery of the prostate may be attributed to androgenically and ontogenically dependent autoantigens may have clinical relevance. This together with knowledge that in the therapeutic management of the patient with prostatic cancer we are confronted with the treatment of an individual who, in the majority of cases, possesses waning immunocompetence, emphasizes the potential significance of evaluating what may be referred to as the 'cryosensitivity' of the prospective cryosurgical patient. At present this 'cryosensitivity' may be said to be dependent upon: (1) concentration of prostatic tissue [secretory(tumour?)]-specific or tumour-associated auto-(neo?) antigen(s); (2) physiologic state (elaboration of androgen), and (3) immunocompetence. It is hopeful that evaluation of these parameters may provide a rational approach toward determining the acceptability of cryosurgery as the treatment of choice in a given patient.
与其他恶性肿瘤相比,前列腺癌患者的研究虽然只受到了粗略的关注,但这些研究表明,宿主反应(部分由免疫生物学因素介导)可能在该疾病的发病机制以及治疗管理中发挥重要作用。近十年来,冷冻手术已逐渐在一定程度上被认可为前列腺癌治疗手段中的有效治疗方式之一。除了对原发性肿瘤的局部破坏外,关于继发性肿瘤细胞破坏(即远处转移)的报道支持了这样的观点,即正如在各种动物物种中所记录的那样,冷冻手术在人类中也可能具有免疫增强作用。尽管我们对通过冷冻手术使宿主对肿瘤的反应产生免疫增强的理解还远未完善,但来自实验研究的信息表明,前列腺冷冻手术后免疫反应的发展可能归因于雄激素依赖性和个体发育依赖性自身抗原,这可能具有临床相关性。再加上我们知道在前列腺癌患者的治疗管理中,我们面对的是一个在大多数情况下免疫能力逐渐下降的个体,这就强调了评估未来接受冷冻手术患者的“冷冻敏感性”的潜在重要性。目前可以说这种“冷冻敏感性”取决于:(1)前列腺组织[分泌性(肿瘤?)]特异性或肿瘤相关自身(新?)抗原的浓度;(2)生理状态(雄激素的分泌),以及(3)免疫能力。有望对这些参数的评估能为确定冷冻手术作为特定患者首选治疗方法的可接受性提供一种合理的方法。